Related Experiment Video
Updated: May 14, 2026
08:53
Synthesis, Functionalization, and Characterization of Fusogenic Porous Silicon Nanoparticles for Oligonucleotide Delivery
Published on: April 16, 2019
Melittin derived peptides for nanoparticle based siRNA transfection
Kirk K Hou1, Hua Pan, Gregory M Lanza
1Computational and Molecular Biophysics, Washington University School of Medicine, St. Louis, MO 63108, USA.
Biomaterials
|February 6, 2013
Summary
A novel peptide, p5RHH, enables efficient and safe small interfering RNA (siRNA) delivery. This peptide-based approach overcomes limitations of traditional agents, offering a promising avenue for developing effective siRNA therapeutics with reduced cytotoxicity.
Area of Science:
- Biotechnology
- Molecular Biology
- Drug Delivery Systems
Background:
- Traditional transfection agents like cationic lipids and polymers show high efficiency but cause significant cytotoxicity.
- Cell-penetrating peptide (CPP) based agents offer improved safety but suffer from low efficiency due to endosomal entrapment.
Purpose of the Study:
- To develop a novel peptide-based small interfering RNA (siRNA) transfection agent with both high efficiency and low cytotoxicity.
- To engineer a modified pore-forming peptide, p5RHH, for effective siRNA complexation and delivery.
Main Methods:
- Melittin, a pore-forming peptide, was modified to create p5RHH, enhancing siRNA binding and reducing cytotoxicity.
- p5RHH/siRNA nanoparticles were formulated and characterized for size (190 nm).
- Transfection efficiency and cytotoxicity were evaluated in B16, HUVEC, and RAW264.7 cells using GFP knockdown assays.
Main Results:
- p5RHH demonstrated high transfection efficiency at low concentrations (5 nM) with negligible cytotoxicity.
- p5RHH/siRNA nanoparticles effectively transfected multiple cell lines, including cancer cells.
- In vitro models showed p5RHH mediated transfection inhibited cancer cell proliferation, angiogenesis, and foam cell formation.
- Nanoparticles maintained size and efficacy in serum, indicating potential for in vivo applications.
Conclusions:
- The developed p5RHH peptide represents a significant advancement in siRNA delivery, offering a safe and efficient alternative to existing transfection methods.
- This peptide engineering strategy holds promise for the development of novel siRNA therapeutics.
- p5RHH mediated siRNA delivery shows potential for therapeutic interventions in cancer and other diseases.
